FindTrial
Sign In

Study of the minimum effective dose of ropivacaine for lower limb nerve block in children

Study of the minimum effective dose of ropivacaine for lower limb nerve block in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300072859
Enrollment
Unknown
Registered
2023-06-27
Start date
2023-07-01
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fracture

Interventions

Dixon Sequential Study:Using the partial coin random method, set the initial concentration of Ropivacaine as 0.4%, the interval as 0.05%, and the volume as 0.5ml/kg. The increase or decrease of Ropiva

Sponsors

Children's Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. 60 children aged 6-18 who plan to undergo knee joint surgery 2. ASA Level I-II

Exclusion criteria

Exclusion criteria: 1. Combined lower limb nerve injury; 2. Skin infection at puncture site 3. Abnormal coagulation function 4. Unable to cooperate with VAS and muscle strength score 5. The child or guardian refuses to sign the informed consent form

Design outcomes

Primary

MeasureTime frame
heart rate;—

Countries

China

Contacts

Public Contactzoutianxiao

Children‘s hospital of shanghai

zouu163@163.com+86 186 6322 9539

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026